{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-256576","form_type":"8-K/A","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.896300+00:00","generated_at":"2026-05-30T00:49:28.393857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neuronetics Q3 rev $18.5M (+4% YoY); cash flow breakeven shifted to Q3 2025","bullets":["Q3 revenue $18.5M (+4% vs Q3 2023); U.S. system revenue $4.1M (+14%), treatment session revenue $13.3M (+2%).","Net loss $(13.3)M ($(0.44)/share) vs $(9.4)M ($(0.33)/share) in Q3 2023; EBITDA $(11.6)M.","Shareholders approved all-stock Greenbrook TMS acquisition; expects cash flow breakeven by Q3 2025 (corrected from Q2).","Q4 2024 standalone revenue guidance $19M-$20M; full-year 2024 guidance $71M-$72M.","188,000 patients treated globally; NeuroStar adolescent TMS data showed 78% response rate at AACAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-256576","json":"https://secwatch.observer/filing/0001193125-24-256576.json","markdown":"https://secwatch.observer/filing/0001193125-24-256576.md","text":"https://secwatch.observer/filing/0001193125-24-256576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524256576/0001193125-24-256576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524256576/d885367d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:49:28.393857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}